Physician profile
Ardy Fenando
NPI 1609362508
$2,266.14
in general payments reported to CMS, 2019-2025
13 companies · $686 in 2025
The $686 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $22.10 · 2023: $219 · 2024: $1,109 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.51 |
| Education | $133.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.78 | 2024-2025 | |
| Glaxosmithkline, LLC. | $296.95 | 2019-2024 | Benlysta |
| Janssen Biotech, INC. | $261.28 | 2024-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $219.83 | 2024-2025 | Uplizna, Tavneos |
| Janssen Scientific Affairs, LLC | $208.53 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $138.47 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $135.00 | 2024 | Arcalyst |
| Ucb, INC. | $112.50 | 2024 | Bimzelx |
| Sobi, INC | $67.21 | 2023 | |
| Lilly USA, LLC | $22.82 | 2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $22.10 | 2020 | |
| Aurinia Pharma U.S., INC. | $18.80 | 2023 | Lupkynis |
| Novo Nordisk INC | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ardy Fenando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.